Reported Saturday, Akero Therapeutics Presented Data Highlighting The Efficacy And Safety Of EFX In Patients With MASH At EASL Congress
Portfolio Pulse from Benzinga Newsdesk
Akero Therapeutics presented promising 96-week data from its Phase 2b HARMONY study on EFX for treating MASH at the EASL Congress. The study showed significant improvements in fibrosis and MASH symptoms, with higher efficacy in the 50 mg EFX dose group.

June 10, 2024 | 7:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akero Therapeutics presented 96-week data from its Phase 2b HARMONY study on EFX for MASH, showing significant improvements in fibrosis and MASH symptoms, particularly in the 50 mg dose group.
The positive results from the Phase 2b HARMONY study, particularly the significant improvements in fibrosis and MASH symptoms, are likely to boost investor confidence and positively impact Akero Therapeutics' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100